Carin A Uyl-de Groot (Carin Uyl-De Groot)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Venues

European journal of haematology

PharmacoEconomics

Drugs

Journal of the National Cancer Institute

Erasmus Universiteit Rotterdam

Erasmus Universiteit Rotterdam (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Erasmus Universiteit Rotterdam Jan 1o 2011

Netherlands

Chair section Health Technology Assessment :: Health Policy & Management

Education History

Erasmus Universiteit Rotterdam Mar 1o 1990 - Sep 15o 1995

Netherlands

PHD :: Health Policy & Management

Publications

Marianne Luyendijk, Agnes Jager, Sanne M Buijs, Sabine Siesling, Carin A Uyl-de Groot, Hedwig M Blommestein
Cost-Effectiveness Analysis of MammaPrint ® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer. PharmacoEconomics (2023)
Brenda Leeneman, Hedwig M Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E Fibbe, Liesbeth Oosten, Carin A Uyl-de Groot, Frederick W Thielen
Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease. European journal of haematology (2023)
Marianne Luyendijk, Otto Visser, Hedwig M Blommestein, Ignace H J T de Hingh, Frank J P Hoebers, Agnes Jager, Gabe S Sonke, Elisabeth G E de Vries, Carin A Uyl-de Groot, Sabine Siesling
Changes in survival in de novo metastatic cancer in an era of new medicines. Journal of the National Cancer Institute (2023)
Tobias B Polak, David G J Cucchi, Jasmin Schelhaas, Syed S Ahmed, Naima Khoshnaw, Joost van Rosmalen, Carin A Uyl-de Groot
Results from Expanded Access Programs: A Review of Academic Literature. Drugs (2023)
Tobias B Polak, David G J Cucchi, Jasmin Schelhaas, Syed S Ahmed, Naima Khoshnaw, Joost van Rosmalen, Carin A Uyl-de Groot
Results from Expanded Access Programs: A Review of Academic Literature. Drugs (2023)
Martijn J H G Simons, Valesca P Retèl, Bram L T Ramaekers, Rogier Butter, Joanne M Mankor, Marthe S Paats, Joachim G J V Aerts, Zakile A Mfumbilwa, Paul Roepman, Veerle M H Coupé, Carin A Uyl-de Groot, Wim H van Harten, Manuela A Joore
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. PharmacoEconomics 39 (12) (2021)
Martijn J H G Simons, Michiel Van De Ven, Veerle Coupé, Manuela Joore, Maarten IJzerman, Erik Koffijberg, Geert Frederix, Carin A Uyl-de Groot, Edwin Cuppen, Wim Van Harten, Valesca P Retèl
Early technology assessment of using whole genome sequencing in personalized oncology. Expert review of pharmacoeconomics & outcomes research 21 (3) (2021)
Laurenske A Visser, Céline Louapre, Carin A Uyl-de Groot, William Ken Redekop
Health-related quality of life of multiple sclerosis patients: a European multi-country study. Archives of public health = Archives belges de sante publique 79 (1) (2021)
Laurenske A Visser, Marc Folcher, Claudia Delgado Simao, Biotza Gutierrez Arechederra, Encarna Escudero, Carin A Uyl-de Groot, William Ken Redekop
The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis. PharmacoEconomics (2021)
Carin A Uyl-de Groot, Rachel Ramsden, Dawn Lee, Janneke Boersma, Sonja Zweegman, Sujith Dhanasiri
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment. European journal of haematology 105 (5) (2020)
Frederick W Thielen, Annemieke van Dongen-Leunis, Alexander M M Arons, Judith R Ladestein, Peter M Hoogerbrugge, Carin A Uyl-de Groot
Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view. European journal of haematology 105 (2) (2020)
Tobias B Polak, Joost van Rosmalen, Carin A Uyl-de Groot
Expanded Access as a source of real-world data: An overview of FDA and EMA approvals. British journal of clinical pharmacology 86 (9) (2020)

Carin A Uyl-de Groot.css-eqlu8i{font-size:small;padding-left:4px;} (Carin Uyl-De Groot)

Publication Activity (10 Years)

Top Topics

Top Venues

Carin A Uyl-de Groot (Carin Uyl-De Groot)